PT  - JOURNAL ARTICLE
AU  - Lourenço, José
AU  - Pinotti, Francesco
AU  - Thompson, Craig
AU  - Gupta, Sunetra
TI  - The impact of host resistance on cumulative mortality and the threshold of herd immunity for SARS-CoV-2
AID  - 10.1101/2020.07.15.20154294
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.15.20154294
4099  - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154294.short
4100  - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154294.full
AB  - It is widely believed that the herd immunity threshold (HIT) required to prevent a resurgence of SARS-CoV-2 is in excess of 50% for any epidemiological setting. Here, we demonstrate that HIT may be greatly reduced if a fraction of the population is unable to transmit the virus due to innate resistance or cross-protection from exposure to seasonal coronaviruses. The drop in HIT is proportional to the fraction of the population resistant only when that fraction is effectively segregated from the general population; however, when mixing is random, the drop in HIT is more precipitous. Significant reductions in expected mortality can also be observed in settings where a fraction of the population is resistant to infection. These results help to explain the large degree of regional variation observed in seroprevalence and cumulative deaths and suggest that sufficient herd-immunity may already be in place to substantially mitigate a potential second wave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNothing to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No details are required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is included.